中文名稱:IRF9抗體 | 英文名稱:Rabbit Polyclonal IRF9 Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 3518 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無 | 靶點(diǎn): IRF9 |
WB | 1/200-1/1000 | Human,Mouse,Rat |
IF | 咨詢技術(shù) | Human,Mouse,Rat |
IHC | 1/50-1/200 | Human,Mouse,Rat |
ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
FCM | 咨詢技術(shù) | Human,Mouse,Rat |
Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
Aliases | p48; IRF-9; ISGF3; ISGF3G |
WB Predicted band size | 44 kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human, Mouse |
Immunogen | Fusion protein of human IRF9 |
Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse panceas tissue, NIH/3T3 cells, Primary antibody: P07392(IRF9 Antibody) at dilution 1/380, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1.5 minutes
The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P07392(IRF9 Antibody) at dilution 1/50. (Original magnification: ×200)
The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07392(IRF9 Antibody) at dilution 1/50. (Original magnification: ×200)
以下是關(guān)于IRF9抗體的3篇參考文獻(xiàn)的簡(jiǎn)要概括(注:文獻(xiàn)信息為示例性虛構(gòu),僅供參考):
1. **"IRF9 Mediates Antiviral Response by Regulating ISGF3 Complex Formation"**
- **作者**: Smith A, et al.
- **摘要**: 本研究利用IRF9特異性抗體,通過免疫共沉淀和Western blot技術(shù),揭示了IRF9在干擾素信號(hào)通路中與STAT1/STAT2形成ISGF3復(fù)合體的關(guān)鍵作用,證實(shí)其在抗病毒基因激活中的必要性。
2. **"Tissue-Specific Expression of IRF9 in Autoimmune Disorders"**
- **作者**: Chen L, et al.
- **摘要**: 通過免疫組化和小鼠模型實(shí)驗(yàn),作者使用IRF9抗體發(fā)現(xiàn)其在自身免疫疾病(如系統(tǒng)性紅斑狼瘡)患者的炎癥組織中高表達(dá),提示IRF9可能作為治療靶點(diǎn)。
3. **"IRF9 Antibody-Based Detection of Transcriptional Regulation in Cancer"**
- **作者**: Gupta R, et al.
- **摘要**: 該研究采用IRF9抗體進(jìn)行ChIP-seq分析,揭示了IRF9在腫瘤細(xì)胞中通過調(diào)控特定干擾素刺激基因(ISGs)影響腫瘤免疫逃逸的分子機(jī)制。
如需真實(shí)文獻(xiàn),建議通過PubMed或Google Scholar搜索關(guān)鍵詞“IRF9 antibody”或“IRF9 function”,并篩選實(shí)驗(yàn)方法部分提及該抗體的研究。
The IRF9 (Interferon Regulatory Factor 9) antibody is a key tool for studying the function of IRF9. a transcription factor critical in mediating interferon (IFN) signaling. IRF9 is a member of the interferon regulatory factor family and forms the ISGF3 (IFN-Stimulated Gene Factor 3) complex with phosphorylated STAT1 and STAT2 upon IFN-α/β stimulation. This complex translocates to the nucleus, binds IFN-stimulated response elements (ISREs), and activates the transcription of interferon-stimulated genes (ISGs) involved in antiviral defense, immune regulation, and cell proliferation. Dysregulation of IRF9 has been linked to autoimmune diseases, viral infections, and cancer, making it a target for therapeutic research.
IRF9 antibodies are widely used in molecular and cellular studies to detect IRF9 expression, localization, and interactions via techniques like Western blotting, immunofluorescence, and co-immunoprecipitation. They are essential for investigating IFN signaling dynamics, JAK-STAT pathway activity, and cellular responses to pathogens or cytokines. Commercially available IRF9 antibodies are typically generated in rabbits or mice using immunogenic peptides corresponding to conserved regions of human or murine IRF9. Validation includes specificity tests using knockout cell lines or siRNA-mediated knockdown. Researchers prioritize antibodies with high affinity, minimal cross-reactivity, and compatibility with their experimental models to ensure reliable data in studies on innate immunity, cancer biology, or inflammatory disorders.
成立日期 | 2024-06-24 (2年) | 注冊(cè)資本 | 50萬(元) |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營(yíng)行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥960.00 |
VIP10年
|
北京索萊寶科技有限公司
|
2025-07-30 | |
¥2824 |
VIP4年
|
上海博爾森生物科技有限公司
|
2025-08-01 | |
詢價(jià) |
VIP3年
|
維百奧(北京)生物科技有限公司
|
2025-08-01 | |
¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 | ||
詢價(jià) |
VIP1年
|
上海切爾齊生物科技有限公司
|
2025-05-30 |